Superinfection during treatment of nosocomial infections with tigecycline

Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):867-71. doi: 10.1007/s10096-010-0942-y. Epub 2010 May 16.

Abstract

We performed a retrospective and observational study of 51 patients treated with tigecycline, as the treatment for nosocomial infections due to multidrug-resistant microorganisms, to evaluate the superinfection rate and their etiologies. Superinfections were diagnosed in 12 (23.5%) patients (seven due to Pseudomonas aeruginosa, 13.7%) and one patient had P. aeruginosa colonization. Five patients with superinfection died (41.6%), three due to superinfections and two to underlying diseases. The superinfection rate observed during tigecycline treatment is higher than that previously reported. Pseudomonas aeruginosa is the most frequent agent, being the cause of 58.5% of all superinfections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteria / classification
  • Bacteria / isolation & purification
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / microbiology
  • Bacterial Infections / mortality
  • Cross Infection / drug therapy*
  • Cross Infection / microbiology
  • Cross Infection / mortality
  • Female
  • Humans
  • Male
  • Middle Aged
  • Minocycline / analogs & derivatives*
  • Minocycline / therapeutic use
  • Prevalence
  • Retrospective Studies
  • Superinfection / epidemiology*
  • Superinfection / microbiology
  • Superinfection / mortality
  • Tigecycline

Substances

  • Anti-Bacterial Agents
  • Tigecycline
  • Minocycline